Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Ítems similars

• Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer
  per: Rastogi, Ichwaku, et al.
  Publicat: (2016)
• Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer
  per: Fong, Jason T., et al.
  Publicat: (2013)
• Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
  per: Baldacci, Simon, et al.
  Publicat: (2017)
• Comparison of Epithelial Mesenchymal Transition Mediated Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cell Lines with Wild Type EGFR and Mutant Type EGFR
  per: Iderzorig, Tsatsral, et al.
  Publicat: (2018)
• MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
  per: Kubo, Takafumi, et al.
  Publicat: (2009)